cyrilzakka/clinical-trials huggingface dataset:
A Comparison of Sedative Drugs for Conscious Sedation During Ultrasound Guided Transbronchial Needle Aspiration

1. Appropriate sedation is needed for medical diagnosis, treatment, and the safety for patients. In non-surgical approaches, benzodiazepines are broadly used for ideal sedated status for patients.

   * However, especially in bronchoscope procedure, continuous monitoring of oxygen saturation is needed to prevent hypoxia due to respiratory distress induced by benzodiazepine.
   * A alpha-2 agonist, dexmedetomidine, which has similar sedative effect, but has less adverse effect of respiratory distress compared to previous agents, was introduced.
2. It is necessary to compare the efficacy and safety of dexmedetomidine with that of midazolam in ultrasound guided transbronchial needle aspiration (EBUS-TBNA).

   * Double blind randomized trial
   * Primary outcome: The number and duration of desaturation, volume of sedative, any use of rescue midazolam, and Ramsay Sedation Scale (RSS) score (for efficacy), and hypertension, tachycardia, any need for mandible support or manual ventilation, and any need for intubation (for safety).


Eligibility Criteria:
Inclusion Criteria:

* Patients who visit Seoul National University Hospital between 2014.04 - 2015.04
* Patients who undergo EBUS-TBNA during the period
* Aged between 18-75
* Patients who meet the criteria of American Society of Anesthesiologists (ASA) physical status classification I-III

Exclusion Criteria:

* American Society of Anesthesiologists (ASA) physical status classification \>3
* Have glomerular filtration rate (GFR) less than 15ml/min 1.73m2 or undergoing hemodialysis
* End stage liver disease.
* Impaired ventricular functions (EF \<30%)
* Patients with baseline oxygen desaturation (resting SpO2 \<90%)
* Asthma or chronic obstructive pulmonary disease or a forced expiratory volume in 1 s (FEV1)of \< 1.0 liter
* Bradycardia \[baseline heart rate (HR)\< 60 beats/min\]
* Hypotension \[baseline systolic arterial pressure (SAP) \< 100 mm Hg\]
* Pregnant state
* Those intolerant or with an allergy to the study drug
* those unable or who refused to give informed consent
"Studio NaVA" - National Study on Quality of Life in Adolescents Affected by Allergic Rhinitis With or Without Asthma

"Studio Nava" is a National Study aiming to assess allergic rhinitis and asthma outcomes on Quality of Life and Quality of Sleep in adolescent patients by means of Web Survey. "Studio Nava" also proposes the innovative use of a web platform ("http://nava.ibim.cnr.it/") that contains all standardized tools (medical-healthcare web form, ACT, Asthma control test; PSQI, Pittsburgh Sleep Quality Index; T5SS, Total Symptom Score; modified SIDRIA for adolescents; Rhinasthma; VAS scale), that will be available for the doctors after the registration to the web platform. Downloaded questionnaires will be delivered to case-patient, asking him/her to fill them during the waiting time of the visit.


Eligibility Criteria:
Inclusion Criteria:

* Clinical cases n°: 600 adolescents affected by allergic rhinitis with/without asthma, from 14 to 17 years age.
* Controls n°: 600 subject (5 for each participant Pediatrician) of the same age range, without respiratory pathology.

Exclusion Criteria:

* Subjects that have not allergic rhinitis with/without asthma diagnosis or are \<14 years old or \>17 years old
Treatment of UC With Novel Therapeutics

This study is a clinical trial being done to investigate the efficacy of drug BRS201 as a treatment in patients with active mild ulcerative colitis. Participation in this study will take 12 weeks long and the study is structured as a crossover study in which participants will take the study drug for 4 weeks and a placebo drug for 4 weeks in a randomized order in the form of an oral medication. Participation may also involve receiving an IV dose of the medication. The study will require participants to attend 7 study visits, all of which will be conducted at a study site. Participation will involve taking an oral medication twice daily, tracking the medication in a log, and getting blood drawn and giving a stool and urine sample for a few lab tests throughout the study.


Eligibility Criteria:
Inclusion Criteria:

* Ability to give consent
* Patients with a confirmed diagnosis of UC for \> 3 months
* History of ≥ 15 cm of colonic involvement as confirmed by colonoscopy
* Disease activity based on calprotectin \> 200
* Allowed medications: mesalamine and sulfasalazine
* Patients with primary sclerosing cholangitis are eligible to enroll

Exclusion Criteria:

* History of uncontrolled hypertension with systolic BP \> 140 and systolic BP \> 90
* Chronic kidney disease as defined by GFR \<55mL/min
* Impaired hepatic function (transaminases elevated \> 2.5 x ULN) unless due to PSC
* Evidence of C. difficile (Negative test result within 1 month is acceptable)
* Infectious Colitis or drug induced colitis
* Crohn's Disease or Indeterminate colitis
* Decompensated liver disease
* Patients who are pregnant or breastfeeding
* Use of rectal therapies
* Patients who have a confirmed malignancy or cancer within 5 years
* Congenital or acquired immunodeficiencies
* Other comorbidities including: Diabetes mellitus, systemic lupus
* High likelihood of colectomy in the next 2 months
* Participation in a therapeutic clinical trial in the preceding 30 days or simultaneously during this trial
* Patients with a history or risk of cardiovascular conditions, including arrhythmia, long QT syndrome, congestive heart failure, stroke, or coronary artery disease
* Prohibited medications: Vitamin C, prednisone, immune modulators (including but not limited to azathioprine, 6-mercaptopurine, mycophenolate mofetil, tacrolimus, cyclosporine, thalidomide, interleukin-10, interleukin-11, and Omvoh or mirikizumab-mrkz) and biologics within the past six weeks including anti-TNF agents within the past six weeks, vedolizumab within the past six weeks, ustekinumab Risankizumab), a JAKi (tofacitinib or upadacitinib), or Velsipity (etrasimod) within the past 6 weeks. (The aim is to treat people who are having disease activity and just on mesalamine.)
Effect of Three Types of Fluoride Varnish in Preventing Early Childhood Caries

This study evaluates and compares the effect of two types of calcium- and phosphate-containing fluoride varnishes to conventional fluoride varnishes in preventing early childhood caries.

Fluoride vanish is the most commonly used professionally applied topical agent. Traditional fluoride vanish application has been reported to exhibit significant caries inhibiting effect in both permanent teeth and primary teeth. The greatest advantage of fluoride vanish is its ability to adhere to tooth tissues for a longer period of time that enables improved fluoride uptake. It allows continuous release of fluoride ions into enamel, dentine, plaque, and saliva.The main action of topical fluoride is to retard demineralization and promote remineralization of enamel by the uptake of calcium and phosphates from saliva. The proposed mechanism of action of topical fluoride is the formation of intraoral calcium fluoride reservoirs, which are retained on enamel and slowly released to inhibit mineral loss during demineralization.

However, the formation of the intraoral calcium fluoride reservoirs is limited by the availability of intraoral calcium and fluoride ions. Low concentration of salivary calcium and phosphate ions leads to mineral deposition only at the surface of enamel as a result of low ion concentration gradient. Deposition of minerals at the surface of enamel alone may not improve the structural properties of the deep part of the incipient carious lesions. Hence, many manufacturers have modified fluoride vanish to include calcium and phosphate ions in an attempt to further improve efficacy of fluoride varnishes.

The in vitro remineralizing effects of calcium- and phosphate-containing fluoride vanishes are encouraging and scientifically sound, a longitudinal, high quality clinical study is needed to verify the laboratory findings.

Eligibility Criteria:
Inclusion Criteria:

* Generally healthy children age between 3-4 of age with unremarkable medical history and at high caries risk with at least one carious lesion (precavitated or cavitated) (Agouropoulos et al 2014). The high caries risk children are chosen because it is anticipated that they will benefit more from the topical fluoride varnish application than the low caries risk children.

Exclusion Criteria:

* Patients who had received professional fluoride application in the past 6 months

  * Patients with underlying medical history or special health care needs
  * Patient who are uncooperative or refuse the treatment
  * Patient who are allergic to milk protein (as MI VarnishTM contains "casein, a milk protein)
  * Patient with contraindication for fluoride varnish e.g. hypersensitivity to colophony and/or any other constituents
  * Patient who have primary teeth with enamel hypoplasia
A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

To evaluate the efficacy, safety tolerability of maintenance therapy with Fluzoparib(A PARP inhibitor) versus placebo in Chinese patients with recurrent ovarian cancer who achieved a complete response (CR) or partial response (PR) after platinum-based chemotherapy


Eligibility Criteria:
Inclusion Criteria:

1. Histologically diagnosed high-grade serous or endometrioid ovarian cancer (including primary peritoneal and fallopian tube cancer)
2. Completion of ≥2 previous platinum-containing regimens
3. Complete response (CR) or partial response (PR) achieved with last platinum-based chemotherapy regimen as determined by investigator
4. Ability to be randomized ≤8 weeks after last dose of platinum

Exclusion Criteria:

1. Prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor
2. Patients who have received other study drug treatment within 4 weeks prior to the first administration(\< 5 elimination half-lives of the study drug molecular targeted anti-cancer drugs).
3. Patients with clinical symptoms of cancer ascites, pleural effusion, who need to drainage, or who have undergone ascites drainage within 2 months prior to the first administration.
Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)

This is a clinical trial to determine the safety and tolerability of MK0683 in combination with gemcitabine and cisplatin and/or carboplatin.


Eligibility Criteria:
Inclusion Criteria:

* Patient must have a histologically-confirmed metastatic or locally advanced non-small cell lung cancer that has not been previously treated with systemic chemotherapy or has received non-platinum and non-gemcitabine based neoadjuvant or adjuvant chemotherapy if the last dose was at least 6 months prior to study enrollment

Exclusion Criteria:

* Patient who has had chemotherapy, radiotherapy, or biological therapy prior to entering the study, except for adjuvant or neoadjuvant chemotherapy, as allowed for treatment of a tumor
Examining Effects of Spinal Fusion on Outcomes Following Total Hip Replacement

The purpose of the study is to explore the long term functional status of people who have had both a spinal fusion procedure and a total hip replacement.

The purpose of the study is to explore the long term functional status of people who have had both a spinal fusion procedure and a total hip replacement. Studies have found that those who have received spinal fusion may have worse outcomes following a total hip replacement than those who have not received a spinal fusion. The information obtained from this study will allow surgeons and researchers to better understand why some who've had a spine fusion have more complications post total hip replacement compared to those who did not have spinal fusion surgery.

Eligibility Criteria:
Inclusion Criteria:

* Willing to come to the Civic Campus for a surgical follow-up visit
* Speaks English and/or French
* Group 1 patients must have had a spine fusion (SF) and total hip arthroplasty (THA)
* Group 2 patients must have had a total hip replacement (THA) and no history of spine fusion (SF)
* Group 3 patients must have had a spine fusion (SF) and no history of total hip arthroplasty (THA)

Exclusion Criteria:

* Patient does not meet all 'inclusion' criteria
* Patient is unable to answer questionnaires
* Unable to get x-rays for other medical reasons
* Severe dementia
Nutritional Management of Post COVID-19 Cognitive Symptoms

The goal of this clinical trial is to learn about in brain "fog" complaints associated with long-COVID in people aged 22-50-years. The main questions it aims to answer are:

* the natural course of brain "fog" complaints
* the effect, if any of supplemental dietary oil on brain "fog" complaints Participants will be asked to undergo some brain testing (X-rays and questions. Treatments they'll be given will be one of two supplemental oils to consume daily.

Researchers will compare outcomes in the two different oil groups to see if it has any effect on brain "fog" complaints.

Randomized placebo-control clinical trial comparing two types of nutritional oil and evaluating the impact, if any, on subjective complaints of long-COVID cognitive changes.

Eligibility Criteria:
Inclusion Criteria:

* confirmed COVID infection, at least 3 months previously, with ongoing cognitive complaints
* all other medical conditions stable, and on stable doses of medications (if required)

Exclusion Criteria:

* COVID infection not confirmed by PCR or Rapid test
* unable to speak English
* pre-COVID cognitve complaints, and/or medical diagnoses affecting cognitive function
Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence

Langerhans cell histiocytosis (LCH) of bone is a benign-tumor-like osteolytic lesion in childhood and adolescence, which is characterized by the aberrant activation of antigen presenting cells. Rather than the multi-system involvements of LCH, no standard or widely-accepted therapeutic regimens were established for LCH of bone. In the previous clinical practice, several LCH patients obtained remarkable pain relief after taking prednisone. Therefore, the investigators aim to conducting a multi-center, open-labelled, randomized-controlled, Phase II study to investigate the efficacy and safety of oral prednisone in treating LCH of bone in children and adolescents. The enrolled patients will be randomly recruited to the following groups: (1) Oral prednisone \[Test group); (2) Regular observation \[Control group\].


Eligibility Criteria:
Inclusion Criteria:

* Pathological diagnosis of Langerhans cell histiocytosis (LCH) of bone;
* Single-system involvement (skeletal system);
* No need of surgical intervention;
* Must be able to swallow tablets;
* Signing informed consent form.

Exclusion Criteria:

* Multi-system involvements (≥2 systems, including bone, liver, spleen, hematologic system, central nerve system);
* Need of surgical intervention (e.g. pathological fracture and/or spinal cord compression)
* Glucocorticoid allergy;
* Immunodeficiency;
* Severe infection;
* Insulin dependent/independent Diabetes;
* Having taken glucocorticoid in the past two weeks;
* Not capable of swallowing tablets;
* Without signed informed consent inform.
Low and High Doses of Prophylactic Vitamin D in Prevention of Osteopenia of Prematurity

In this study the effects of low and high doses of prophylactic vitamin D on biochemical and radiological manifestations of osetopenia of prematurity will be tested.

The study will be conducted on (80) preterm infants that fulfill the eligibility criteria and delivered at Alexandria University Maternity Hospital (AUMH).

Eligibility Criteria:
Inclusion Criteria:

* Newborns with gestational age of ≤ 32 weeks and birth weight ≤ 1500 g.

Exclusion Criteria:

* Newborns whose mothers were taking specific medications interacting with vitamin D metabolism (e.g., anticonvulsants, diuretics)
* Being NPO (nothing per oral) for more than 2 wks
* Gestational age more than 32 weeks
* Birth weight more than 1500 grams
Cannabidiol Effects on Learning and Anxiety

To examine the extent to which Cannabidiol (CBD) enhances fear conditioning extinction in college undergraduates who show elevated social anxiety. Undergraduates who display elevated social anxiety on standard assessments will be recruited at the University of Connecticut. All participants will be put in a standard fear conditioning paradigm where they are conditioned to fear a face that occasionally is followed by a shock to their wrist. The other face never is paired with a shock. After everybody learns this, half of the participants will receive 600 mg CBD Isolate Gel Capsules one time, and the other half will receive a placebo dose. Participants will then be presented with the faces with no shocks, and the rate and duration of extinction as measured by electrodermal response as well as subjective fear ratings via a visual analogue scale will be examined. It is hypothesized that participants that receive CBD will display enhanced extinction compared to the placebo group, as evidenced by reduced electrodermal response and reduced visual analogue fear ratings.


Eligibility Criteria:
Inclusion Criteria:

* 18-50 years of age

Exclusion Criteria:

1. Difficulties seeing a computer screen
2. Anyone currently taking CBD within the last 24 hours.
3. Anyone using any cannabis product within the last 24 hours.
4. Heart problems or heart disease
5. A neurological disorder such as epilepsy, stroke, multiple sclerosis, tumor, vascular malformations, aneurysm
6. Are currently pregnant or breast-feeding
An Investigation Into the Efficacy of a Botanical Supplement to Provide Period Relief

Women often experience significant pain during their periods which can significantly impact on quality of life. In this study, two products that are used to alleviate period pain will be examined. One test product is botanically based, and the other is a traditional over-the-counter pain reliever with additional components added to support less painful periods. The trial will be a cross-over trial where participants will use the botanical product before, during, and after their first period. Participants will use the botanical product alongside a traditional over-the-counter period product during their second period. Participants will answer surveys and have blood drawn at a third-party lab to answer the main objectives of this trial.


Eligibility Criteria:
Inclusion Criteria:

* Female between 18-40 years of age.
* Must be in good health with no significant chronic conditions and a BMI under 35.
* Must experience period pain and other PMS symptoms.
* Must have a regular menstrual cycle with a bleed week.
* If using hormonal contraception, must do so for at least three months
* If using oral contraception, must allow for bleed week.
* Must be able to predict their bleed week.
* Willing to abstain from strenuous exercise 24 hours before each of the three blood draws in this trial.

Exclusion Criteria:

* Suffers from pre-existing conditions that would prevent them from adhering to the protocol.
* Anyone with known severe allergic reactions.
* Anyone with a previous negative experience with acetaminophen.
* Unwilling to follow the study protocol.
* Currently pregnant, breastfeeding, or wanting to become pregnant for the duration of the study.
* Anyone who uses other supplements for period pain and PMS symptoms.
* Current use of an extended activity hormonal contraception (examples include Depo-provera or Nexplanon.
Fascial Manipulation on the Treatment of Carpal Tunnel Syndrome

The trial aims to evaluate the effectiveness of Fascial Manipulation on pain reduction, functional recovery and nerve conduction of patients with Carpal Tunnel Syndrome (CTS). Visual Analogue Scale (VAS), Disabilities of the Arm, Shoulder and Hand scale (DASH), Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) and Electroneuromyography were assessed.

The study is blind for the patient and the raters.

This is a prospective, randomized, placebo controlled, rater blind trial to evaluate the effectiveness of Fascial Manipulation as a therapy for CTS. Fascial Manipulation is an intense friction performed by the elbows or the distal extremities of the interphalangeal articulation of the index finger for some minutes as to promote hyperemia to restore the collagen fibers ability to slide against each other. The friction lasts from 2 to 4 minutes.

In this trial, 14 patients were randomized in two groups: The intervention group received fascial manipulation for CTS and the other group, received fascial manipulation on spots not related to CTS. This last group was the placebo control group.

The treatment was performed once a week for 5 weeks consecutively and the follow up visits for the assessments were performed 10 days and 3 months after the end of the treatment.

Eligibility Criteria:
Inclusion Criteria:

* CTS degrees Ia, Ib and II diagnosis according to clinical evaluation and electroneuromyography;
* Wrist and finger paresthesia for more than 3 months prior to screening visit;
* Moderate to intense pain: VAS\>4.
* Ability to understand and respond to the questionnaires used in the trial;
* Ability to understand the Informed Consent Form;
* Sign the Informed Consent Form.

Exclusion Criteria:

* Psychiatric disorders;
* Fibromyalgia;
* Rheumatologic diseases;
* Other conditions related to CTS, as renal failure, diabetes, acromegaly, hyperthyroidism, multiple myeloma;
* History of neoplasia;
* History of surgery at Carpal Tunnel;
* History of use of illegal drugs;
* History of chronic use of corticosteroids;
* Corticosteroid infiltration one month prior to inclusion in the trial.
Characterization of Endocarditis to Streptococci and Impact of the CMI on the Future of the Patients

The infectious endocarditis is a grave infection the incidence of which is at present esteemed at 30-100 episodes by million inhabitants a year.

This infection is marked with a heavy morbi-mortality.Preliminary studies seem to show an abnormally high death rate at the patients presenting an infectious endocarditis to streptococci with an inhibitive minimal concentration raised to the amoxicilline. The aim of the study is to describe the epidemiology and the clinical presentations of the patients presenting an endocarditis to streptococci


Eligibility Criteria:
Inclusion Criteria:

* age \> 18 years
* endocartitis with steptococci with Duke's criteria

Exclusion Criteria:

* age \< 18 years
* suspiscious endocarditis without Duke's criteria